Nucala denied as duplicate or overlapping therapy by Cigna?

Cigna's specific coverage criteria for nucala are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Nucala as "Duplicate Therapy" — and Why You Can Appeal

Nucala (mepolizumab) is an anti-IL-5 biologic approved for severe eosinophilic asthma (and select other eosinophilic conditions). A duplicate-therapy denial typically means Cigna's system identified another biologic already on file — such as another anti-IL-5 or anti-IL-4/13 agent — and flagged the Nucala claim as redundant. However, biologics in the same or overlapping class are not interchangeable for every patient: a patient may have trialed another agent with inadequate response, or the prescriber may have clinical reasons for this specific agent. These distinctions must be explicitly documented in the appeal.

## Your Federal Appeal Rights

• Internal appeal (ACA §2719 / ERISA §503): You have the right to a full-and-fair internal review. File within the deadline on your denial notice.
• External review: After internal remedies are exhausted — or if Cigna fails to resolve within statutory deadlines — request IRO external review. The external-review window is generally within approximately four months of a final adverse determination.
• Expedited review: Available if exacerbation frequency or severity makes delay medically hazardous.

## Concrete Appeal Steps

1. Obtain Cigna's published coverage policy for Nucala and for the agent Cigna claims duplicates it. 2. Confirm with the prescriber whether the other agent is current, discontinued, or was trialed and failed. 3. If the other biologic was trialed and failed, document it thoroughly — dates, doses as recorded in the chart, and the specific inadequate outcome. 4. Submit a formal internal appeal with a clinical letter explaining why Nucala is not duplicative.

## Documentation to Gather

• Current medication list: Clarify what other biologic is on file and its status (active, discontinued, or prior trial).
• Prior biologic trial history: Dates, chart documentation of inadequate asthma control, exacerbation records, and reason for discontinuation.
• Diagnosis confirmation: Confirmed severe eosinophilic asthma (or applicable indication) with eosinophil count documented in the chart.
• Clinical severity: Exacerbation history, hospitalization, oral corticosteroid burden, pulmonary function trends.
• Prescriber letter: Explains the clinical distinction between the agents and why Nucala is not duplicative for this patient.

## Criteria-Mapping Structure

Consult Nucala's FDA-approved prescribing label and Cigna's current coverage policy. For each criterion, document the chart evidence. If the appeal turns on a prior-biologic failure, structure the argument as: [agent name] was prescribed on [date], inadequate response documented on [date per chart], Nucala selected based on [prescriber's clinical rationale]. Reference the applicable asthma guideline organization generically (e.g., the applicable GINA or specialist society guideline) to support the rationale for biologic selection.